Kaslow D C
Malaria Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Immunol Lett. 1990 Aug;25(1-3):83-6. doi: 10.1016/0165-2478(90)90096-9.
Immunogenicity of sexual stage antigens and boosting of transmission blocking antibodies following a natural infection are two critical factors in the design of an effective, subunit vaccine to block the transmission of malaria from man to mosquito. Immunogenicity and boosting are both T cell-dependent. Antigens, such as the 230-kDa, the 48/45-kDa, and the 40/10-kDa, expressed early in the extracellular forms of the sexual stage of Plasmodium falciparum, have limited immunogenicity in humans and in mice. In contrast, Pfs25, expressed predominantly in zygotes and ookinetes, has widespread immunogenicity in mice. Pfs25 expressed by a recombinant vaccinia virus (vSIDK) is also widely immunogenic in mice, and induces transmission blocking antibodies following multiple inoculations with vSIDK. The implications of these immunogenicity data are discussed relative to the design of an effective transmission blocking vaccine.
疟原虫有性阶段抗原的免疫原性以及自然感染后传播阻断抗体的增强,是设计一种有效亚单位疫苗以阻断疟疾从人传播至蚊子过程中的两个关键因素。免疫原性和增强作用均依赖于T细胞。恶性疟原虫有性阶段细胞外形式早期表达的抗原,如230-kDa、48/45-kDa和40/10-kDa,在人和小鼠中免疫原性有限。相比之下,主要在合子和动合子中表达的Pfs25在小鼠中具有广泛的免疫原性。由重组痘苗病毒(vSIDK)表达的Pfs25在小鼠中也具有广泛的免疫原性,并且在多次接种vSIDK后可诱导产生传播阻断抗体。相对于有效传播阻断疫苗的设计,讨论了这些免疫原性数据的意义。